Skip to main content
Top
Published in: Supportive Care in Cancer 3/2010

01-03-2010 | Original Article

Impact of improved nutritional status on survival in ovarian cancer

Authors: Digant Gupta, Christopher G. Lis, Pankaj G. Vashi, Carolyn A. Lammersfeld

Published in: Supportive Care in Cancer | Issue 3/2010

Login to get access

Abstract

Purpose

Malnutrition is a common occurrence in ovarian cancer and is a major cause of morbidity and mortality. We evaluated the impact of improvement in nutritional status on ovarian cancer survival.

Methods

A retrospective chart review was performed on a case series of 98 ovarian cancer patients. Subjective global assessment (SGA) was used to evaluate nutritional status. Patients were classified as well-nourished (SGA A) or moderately–severely malnourished (SGA B/C). Patients were classified into four groups: (1) well-nourished at baseline and 3 months, (2) malnourished at baseline, well-nourished at 3 months, (3) malnourished at baseline and 3 months, (4) well-nourished at baseline, malnourished at 3 months.

Results

Of 98 patients, 20 were newly diagnosed while 78 had received prior treatment. The median age at presentation was 55.3 years. At baseline, the median survival for SGA A (N = 46) was 20.3 months while for SGA B/C (N = 52) was 9.8 months (p = 0.03). At 3 months, the median survival for SGA A (N = 63) was 19.9 months while for SGA B/C (N = 35) was 3.7 months (p < 0.001). Patients with an improved nutritional status at 3 months had a significantly better survival than those with deteriorated nutritional status independent of age, stage at diagnosis, prior treatment history, and tumor response as determined by CA125.

Conclusions

Improvement in nutritional status is associated with better survival. Consequently, our findings lend support to the importance of aggressive nutritional intervention in improving patient outcomes in oncology.
Literature
1.
go back to reference Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407–1427PubMedCrossRef Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407–1427PubMedCrossRef
2.
go back to reference Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K (2006) Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521–528PubMed Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K (2006) Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521–528PubMed
4.
go back to reference Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517–523PubMed Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517–523PubMed
5.
go back to reference Hannibal CG, Cortes R, Engholm G, Kjaer SK (2008) Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978–2002. Acta Obstet Gynecol Scand 87:1353–1360CrossRefPubMed Hannibal CG, Cortes R, Engholm G, Kjaer SK (2008) Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978–2002. Acta Obstet Gynecol Scand 87:1353–1360CrossRefPubMed
6.
go back to reference du Bois A, Rochon J, Pfisterer J, Hoskins WJ (2008) Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 112:422–436PubMed du Bois A, Rochon J, Pfisterer J, Hoskins WJ (2008) Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 112:422–436PubMed
9.
go back to reference Persson C, Glimelius B (2002) The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 22:3661–3668PubMed Persson C, Glimelius B (2002) The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 22:3661–3668PubMed
10.
go back to reference Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ (2007) Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 15:301–307. doi:10.1007/s00520-006-0153-3 CrossRefPubMed Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ (2007) Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 15:301–307. doi:10.​1007/​s00520-006-0153-3 CrossRefPubMed
12.
go back to reference Ollenschlager G, Viell B, Thomas W, Konkol K, Burger B (1991) Tumor anorexia: causes, assessment, treatment. Recent Results Cancer Res 121:249–259PubMed Ollenschlager G, Viell B, Thomas W, Konkol K, Burger B (1991) Tumor anorexia: causes, assessment, treatment. Recent Results Cancer Res 121:249–259PubMed
13.
go back to reference Heys SD, Schofield AC, Wahle KW, Garcia-Caballero M (2005) Nutrition and the surgical patient: triumphs and challenges. Surgeon 3:139–144CrossRefPubMed Heys SD, Schofield AC, Wahle KW, Garcia-Caballero M (2005) Nutrition and the surgical patient: triumphs and challenges. Surgeon 3:139–144CrossRefPubMed
16.
17.
go back to reference Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51–S63PubMed Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51–S63PubMed
19.
go back to reference MacDonald N (2003) Is there evidence for earlier intervention in cancer-associated weight loss? J Support Oncol 1:279–286PubMed MacDonald N (2003) Is there evidence for earlier intervention in cancer-associated weight loss? J Support Oncol 1:279–286PubMed
21.
go back to reference Ottery FD (1994) Cancer cachexia: prevention, early diagnosis, and management. Cancer Pract 2:123–131PubMed Ottery FD (1994) Cancer cachexia: prevention, early diagnosis, and management. Cancer Pract 2:123–131PubMed
22.
go back to reference Ottery FD (1995) Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 22:98–111PubMed Ottery FD (1995) Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 22:98–111PubMed
24.
go back to reference Chima CS, Barco K, Dewitt ML, Maeda M, Teran JC, Mullen KD (1997) Relationship of nutritional status to length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc 97:975–978. doi:10.1016/S0002-8223(97)00235-6 CrossRefPubMed Chima CS, Barco K, Dewitt ML, Maeda M, Teran JC, Mullen KD (1997) Relationship of nutritional status to length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc 97:975–978. doi:10.​1016/​S0002-8223(97)00235-6 CrossRefPubMed
27.
28.
go back to reference Isenring EA, Bauer JD, Capra S (2007) Nutrition support using the American Dietetic Association medical nutrition therapy protocol for radiation oncology patients improves dietary intake compared with standard practice. J Am Diet Assoc 107:404–412. doi:10.1016/j.jada.2006.12.007 CrossRefPubMed Isenring EA, Bauer JD, Capra S (2007) Nutrition support using the American Dietetic Association medical nutrition therapy protocol for radiation oncology patients improves dietary intake compared with standard practice. J Am Diet Assoc 107:404–412. doi:10.​1016/​j.​jada.​2006.​12.​007 CrossRefPubMed
29.
go back to reference Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE (2005) Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 17:639–645. doi:10.1016/j.clon.2005.03.015 Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE (2005) Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 17:639–645. doi:10.​1016/​j.​clon.​2005.​03.​015
31.
go back to reference Ravasco P, Monteiro-Grillo I, Marques VP, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668. doi:10.1002/hed.20221 CrossRefPubMed Ravasco P, Monteiro-Grillo I, Marques VP, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668. doi:10.​1002/​hed.​20221 CrossRefPubMed
33.
go back to reference Goncalves Dias MC, Fatima Nunes MM, Nadalin W, Waitzberg DL (2005) Nutritional intervention improves the caloric and proteic ingestion of head and neck cancer patients under radiotherapy. Nutr Hosp 20:320–325PubMed Goncalves Dias MC, Fatima Nunes MM, Nadalin W, Waitzberg DL (2005) Nutritional intervention improves the caloric and proteic ingestion of head and neck cancer patients under radiotherapy. Nutr Hosp 20:320–325PubMed
34.
go back to reference Norman K, Stubler D, Baier P, Schutz T, Ocran K, Holm E, Lochs H, Pirlich M (2006) Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer—a double blind randomised controlled trial. Clin Nutr 25:596–605. doi:10.1016/j.clnu.2006.01.014 CrossRefPubMed Norman K, Stubler D, Baier P, Schutz T, Ocran K, Holm E, Lochs H, Pirlich M (2006) Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer—a double blind randomised controlled trial. Clin Nutr 25:596–605. doi:10.​1016/​j.​clnu.​2006.​01.​014 CrossRefPubMed
35.
go back to reference Sun LC, Shih YL, Lu CY, Hsieh JS, Chuang JF, Chen FM, Ma CJ, Wang JY (2008) Randomized, controlled study of branched chain amino acid-enriched total parenteral nutrition in malnourished patients with gastrointestinal cancer undergoing surgery. Am Surg 74:237–242PubMed Sun LC, Shih YL, Lu CY, Hsieh JS, Chuang JF, Chen FM, Ma CJ, Wang JY (2008) Randomized, controlled study of branched chain amino acid-enriched total parenteral nutrition in malnourished patients with gastrointestinal cancer undergoing surgery. Am Surg 74:237–242PubMed
38.
go back to reference Gupta D, Lis CG, Dahlk SL, Vashi PG, Grutsch JF, Lammersfeld CA (2004) Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. Br J Nutr 92:957–962. doi:10.1079/BJN20041292 CrossRefPubMed Gupta D, Lis CG, Dahlk SL, Vashi PG, Grutsch JF, Lammersfeld CA (2004) Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. Br J Nutr 92:957–962. doi:10.​1079/​BJN20041292 CrossRefPubMed
39.
go back to reference Gupta D, Lammersfeld CA, Burrows JL, Dahlk SL, Vashi PG, Grutsch JF, Hoffman S, Lis CG (2004) Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. Am J Clin Nutr 80:1634–1638PubMed Gupta D, Lammersfeld CA, Burrows JL, Dahlk SL, Vashi PG, Grutsch JF, Hoffman S, Lis CG (2004) Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. Am J Clin Nutr 80:1634–1638PubMed
40.
go back to reference Gupta D, Lammersfeld CA, Vashi PG, King J, Dahlk SL, Grutsch JF, Lis CG (2008) Bioelectrical impedance phase angle as a prognostic indicator in breast cancer. BMC Cancer 8:249CrossRefPubMed Gupta D, Lammersfeld CA, Vashi PG, King J, Dahlk SL, Grutsch JF, Lis CG (2008) Bioelectrical impedance phase angle as a prognostic indicator in breast cancer. BMC Cancer 8:249CrossRefPubMed
41.
go back to reference Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43:163–168PubMed Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43:163–168PubMed
42.
44.
go back to reference Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 12:CR240–CR247PubMed Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 12:CR240–CR247PubMed
45.
go back to reference Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43:163–168PubMed Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43:163–168PubMed
46.
go back to reference Lam PT, Leung MW, Tse CY (2007) Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Med J 13:453–459PubMed Lam PT, Leung MW, Tse CY (2007) Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Med J 13:453–459PubMed
48.
go back to reference Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14:381–389. doi:10.1245/s10434-006-9093-x CrossRefPubMed Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14:381–389. doi:10.​1245/​s10434-006-9093-x CrossRefPubMed
52.
go back to reference Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN (1984) Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr 8:153–159. doi:10.1177/0148607184008002153 CrossRefPubMed Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN (1984) Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr 8:153–159. doi:10.​1177/​0148607184008002​153 CrossRefPubMed
54.
go back to reference Barbosa-Silva MC, de Barros AJ (2002) Subjective nutrition assessment: part 1—a review of its validity after two decades of use. Arq Gastroenterol 39:181–187PubMed Barbosa-Silva MC, de Barros AJ (2002) Subjective nutrition assessment: part 1—a review of its validity after two decades of use. Arq Gastroenterol 39:181–187PubMed
Metadata
Title
Impact of improved nutritional status on survival in ovarian cancer
Authors
Digant Gupta
Christopher G. Lis
Pankaj G. Vashi
Carolyn A. Lammersfeld
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0670-y

Other articles of this Issue 3/2010

Supportive Care in Cancer 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine